Compare Stocks: TRDA, SVRA, MLTX, and JANX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
JANX Janux Therapeutics	$16.59 -1.6%	$16.99	$12.12 ▼ $35.34	$1.03B	2.53	882,581 shs	2.45 million shs
MLTX MoonLake Immunotherapeutics	$12.39 +0.3%	$16.55	$5.95 ▼ $62.75	$1.05B	1.04	1.35 million shs	1.80 million shs
SVRA Savara	$5.37 -0.9%	$5.49	$3.34 ▼ $7.01	$1.11B	0.25	1.34 million shs	2.18 million shs
TRDA Entrada Therapeutics	$6.75 -2.2%	$6.96	$5.08 ▼ $16.45	$268.66M	-0.25	282,553 shs	354,430 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
JANX Janux Therapeutics	-1.60%	-2.98%	-5.31%	+16.67%	-29.28%
MLTX MoonLake Immunotherapeutics	+0.32%	-0.96%	-25.99%	-35.50%	-75.79%
SVRA Savara	-0.92%	+1.32%	-3.76%	-2.36%	+49.17%
TRDA Entrada Therapeutics	-2.17%	-0.74%	-13.24%	-4.80%	+32.61%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
JANX Janux Therapeutics	$16.59 -1.6%	$16.99	$12.12 ▼ $35.34	$1.03B	2.53	882,581 shs	2.45 million shs
MLTX MoonLake Immunotherapeutics	$12.39 +0.3%	$16.55	$5.95 ▼ $62.75	$1.05B	1.04	1.35 million shs	1.80 million shs
SVRA Savara	$5.37 -0.9%	$5.49	$3.34 ▼ $7.01	$1.11B	0.25	1.34 million shs	2.18 million shs
TRDA Entrada Therapeutics	$6.75 -2.2%	$6.96	$5.08 ▼ $16.45	$268.66M	-0.25	282,553 shs	354,430 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
JANX Janux Therapeutics	-1.60%	-2.98%	-5.31%	+16.67%	-29.28%
MLTX MoonLake Immunotherapeutics	+0.32%	-0.96%	-25.99%	-35.50%	-75.79%
SVRA Savara	-0.92%	+1.32%	-3.76%	-2.36%	+49.17%
TRDA Entrada Therapeutics	-2.17%	-0.74%	-13.24%	-4.80%	+32.61%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
JANX Janux Therapeutics	2.67	Moderate Buy	$36.46	119.78% Upside
MLTX MoonLake Immunotherapeutics	2.44	Hold	$24.57	98.32% Upside
SVRA Savara	2.88	Moderate Buy	$10.00	86.22% Upside
TRDA Entrada Therapeutics	2.50	Moderate Buy	$17.75	162.96% Upside

Current Analyst Ratings Breakdown

Latest TRDA, SVRA, MLTX, and JANX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/16/2026	TRDA Entrada Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/16/2026	MLTX MoonLake Immunotherapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
8/31/2026	TRDA Entrada Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/24/2026	JANX Janux Therapeutics	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Peer Perform ➝ Outperform	$23.00
8/24/2026	JANX Janux Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/21/2026	MLTX MoonLake Immunotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/13/2026	TRDA Entrada Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/13/2026	MLTX MoonLake Immunotherapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$45.00 ➝ $50.00
8/12/2026	TRDA Entrada Therapeutics	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$11.00
8/7/2026	MLTX MoonLake Immunotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
8/7/2026	JANX Janux Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$35.00

(Data available from 9/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
JANX Janux Therapeutics	$10M	101.43	N/A	N/A	$15.91 per share	1.04
MLTX MoonLake Immunotherapeutics	N/A	N/A	N/A	N/A	$4.27 per share	N/A
SVRA Savara	N/A	N/A	N/A	N/A	$1.00 per share	N/A
TRDA Entrada Therapeutics	$25.42M	10.34	N/A	N/A	$8.01 per share	0.84

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
JANX Janux Therapeutics	-$113.62M	-$1.64	N/A	N/A	N/A	N/A	-11.89%	-11.13%	11/5/2026 (Estimated)
MLTX MoonLake Immunotherapeutics	-$227.32M	-$3.84	N/A	N/A	N/A	N/A	-82.53%	-58.17%	11/4/2026 (Estimated)
SVRA Savara	-$118.84M	-$0.58	N/A	N/A	N/A	N/A	-90.28%	-68.95%	11/11/2026 (Estimated)
TRDA Entrada Therapeutics	-$143.75M	-$3.96	N/A	N/A	N/A	-3,537.73%	-57.61%	-46.54%	11/5/2026 (Estimated)

Latest TRDA, SVRA, MLTX, and JANX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	SVRA Savara	-$0.1413	-$0.16	-$0.0188	-$0.16	$2.00 million	N/A
8/10/2026	Q2 2026	MLTX MoonLake Immunotherapeutics	-$0.9086	-$0.84	+$0.0686	-$0.84	N/A	N/A
8/6/2026	Q2 2026	JANX Janux Therapeutics	-$0.2513	-$0.35	-$0.0987	-$0.35	$19.08 million	$10.27 million
8/5/2026	Q2 2026	TRDA Entrada Therapeutics	-$0.9738	-$1.01	-$0.0363	-$1.01	$2.32 million	$0.90 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
JANX Janux Therapeutics	N/A	N/A	N/A	N/A	N/A
MLTX MoonLake Immunotherapeutics	N/A	N/A	N/A	N/A	N/A
SVRA Savara	N/A	N/A	N/A	N/A	N/A
TRDA Entrada Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
JANX Janux Therapeutics	N/A	16.35	16.35
MLTX MoonLake Immunotherapeutics	0.23	12.56	12.56
SVRA Savara	0.21	10.13	10.13
TRDA Entrada Therapeutics	N/A	10.89	10.89

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
JANX Janux Therapeutics	75.39%
MLTX MoonLake Immunotherapeutics	93.85%
SVRA Savara	87.93%
TRDA Entrada Therapeutics	86.39%

Insider Ownership

Company	Insider Ownership
JANX Janux Therapeutics	7.90%
MLTX MoonLake Immunotherapeutics	10.40%
SVRA Savara	5.30%
TRDA Entrada Therapeutics	9.49%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
JANX Janux Therapeutics	113	61.14 million	56.31 million	Optionable
MLTX MoonLake Immunotherapeutics	130	85.11 million	76.26 million	Optionable
SVRA Savara	70	205.46 million	194.57 million	Optionable
TRDA Entrada Therapeutics	152	38.94 million	35.24 million	Optionable

TRDA, SVRA, MLTX, and JANX Headlines

Recent News About These Companies

Entrada Therapeutics, Inc.: Entrada Therapeutics Announces Recipients of Fourth Annual DREAMS Grant Program

September 10, 2026 | finanznachrichten.de

Entrada Therapeutics Announces Recipients of Fourth Annual DREAMS Grant Program

September 10, 2026 | globenewswire.com

Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Bioventures 2018 L.P. Mpm Sells 28,837 Shares of Stock

September 10, 2026 | insidertrades.com

Insider Selling: Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Sells $205,607.81 in Stock

September 9, 2026 | marketbeat.com

Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Bioventures 2018 L.P. Mpm Sells 38,500 Shares

September 9, 2026 | marketbeat.com

Bioventures 2018 L.P. Mpm Sells 192,500 Shares of Entrada Therapeutics (NASDAQ:TRDA) Stock

September 9, 2026 | marketbeat.com

Analysts Conflicted on These Healthcare Names: Definitive Healthcare Corp (DH) and Entrada Therapeutics Inc (TRDA)

September 5, 2026 | theglobeandmail.com

Entrada Therapeutics (NASDAQ:TRDA) Upgraded at Wall Street Zen

September 5, 2026 | marketbeat.com

Insider Selling: Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Sells $180,691.89 in Stock

September 4, 2026 | insidertrades.com

BlackRock Inc. Invests $19.01 Million in Entrada Therapeutics, Inc. $TRDA

September 4, 2026 | marketbeat.com

Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Sells $180,691.89 in Stock

September 3, 2026 | marketbeat.com

Insider Selling: Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Sells $205,361.28 in Stock

September 3, 2026 | marketbeat.com

Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Bioventures 2018 L.P. Mpm Sells 32,263 Shares of Stock

September 3, 2026 | marketbeat.com

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 2, 2026 | globenewswire.com

Insider Selling: Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Sells $26,168.33 in Stock

September 1, 2026 | insidertrades.com

Insider Selling: Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Sells $26,168.33 in Stock

August 31, 2026 | marketbeat.com

Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Bioventures 2018 L.P. Mpm Sells 38,922 Shares

August 31, 2026 | marketbeat.com

Bioventures 2018 L.P. Mpm Sells 44,259 Shares of Entrada Therapeutics (NASDAQ:TRDA) Stock

August 31, 2026 | marketbeat.com

300,575 Shares in Entrada Therapeutics, Inc. $TRDA Bought by Nantahala Capital Management LLC

August 29, 2026 | marketbeat.com

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Given Consensus Rating of "Moderate Buy" by Brokerages

August 29, 2026 | marketbeat.com

Insider Selling: Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Sells $102,857.14 in Stock

August 27, 2026 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRDA, SVRA, MLTX, and JANX Company Descriptions

Janux Therapeutics NASDAQ:JANX

$16.59 -0.27 (-1.60%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$16.59 0.00 (0.00%)

As of 09/18/2026 07:30 PM Eastern

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

MoonLake Immunotherapeutics NASDAQ:MLTX

$12.39 +0.04 (+0.32%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$12.36 -0.03 (-0.20%)

As of 09/18/2026 07:53 PM Eastern

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

Savara NASDAQ:SVRA

$5.37 -0.05 (-0.92%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$5.44 +0.06 (+1.21%)

As of 09/18/2026 07:30 PM Eastern

Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.

Entrada Therapeutics NASDAQ:TRDA

$6.75 -0.15 (-2.17%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$6.76 +0.01 (+0.15%)

As of 09/18/2026 04:21 PM Eastern

Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TRDA, SVRA, MLTX, and JANX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TRDA, SVRA, MLTX, and JANX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TRDA, SVRA, MLTX, and JANX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRDA, SVRA, MLTX, and JANX Company Descriptions

Janux Therapeutics NASDAQ:JANX

MoonLake Immunotherapeutics NASDAQ:MLTX

Savara NASDAQ:SVRA

Entrada Therapeutics NASDAQ:TRDA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TRDA, SVRA, MLTX, and JANX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TRDA, SVRA, MLTX, and JANX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TRDA, SVRA, MLTX, and JANX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRDA, SVRA, MLTX, and JANX Company Descriptions

Janux Therapeutics NASDAQ:JANX

MoonLake Immunotherapeutics NASDAQ:MLTX

Savara NASDAQ:SVRA

Entrada Therapeutics NASDAQ:TRDA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools